|
| Status |
Public on Jul 23, 2018 |
| Title |
MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
Genome binding/occupancy profiling by high throughput sequencing
|
| Summary |
This SuperSeries is composed of the SubSeries listed below.
|
| |
|
| Overall design |
Refer to individual Series
|
| |
|
| Citation(s) |
29431698 |
| |
| Submission date |
Nov 17, 2017 |
| Last update date |
May 15, 2019 |
| Contact name |
Richard Koche |
| E-mail(s) |
kocher@mskcc.org
|
| Organization name |
Memorial Sloan Kettering Cancer Center
|
| Street address |
417 E. 68th St.
|
| City |
New York |
| State/province |
New York |
| ZIP/Postal code |
10065 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL16791 |
Illumina HiSeq 2500 (Homo sapiens) |
|
| Samples (30)
|
|
| This SuperSeries is composed of the following SubSeries: |
| GSE94453 |
MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia [mutant MEF2C] |
| GSE107071 |
MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia [inhibitor MRT199665] |
| GSE107072 |
MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia [ATAC-seq] |
|
| Relations |
| BioProject |
PRJNA418953 |
Less...
More...